Which option is not typically part of post-market safety monitoring?

Which option is not typically part of post-market safety monitoring?

• A. Monitoring adverse events
• B. Collecting real-world performance data
• C. Conducting routine premarket trials
• D. Issuing safety communications as needed

Answer: (C)

Post-market safety monitoring, also known as pharmacovigilance, is the ongoing process of tracking a medical product’s safety once it’s available to patients. It involves systems for monitoring adverse events, collecting real-world performance data from broad use, and issuing safety communications when needed to inform clinicians and patients. Routine premarket trials, on the other hand, are conducted during product development before approval to establish safety and efficacy in controlled settings. They are not part of post-market surveillance because they occur before the product is on the market.

Post-market safety monitoring, also known as pharmacovigilance, is the ongoing process of tracking a medical product’s safety once it’s available to patients. It involves systems for monitoring adverse events, collecting real-world performance data from broad use, and issuing safety communications when needed to inform clinicians and patients. Routine premarket trials, on the other hand, are conducted during product development before approval to establish safety and efficacy in controlled settings. They are not part of post-market surveillance because they occur before the product is on the market.